Huntington disease (HD) is a neurodegenerative disorder caused by an elongated polyglutamine tract in huntingtin (htt). htt normally undergoes different posttranslational modifications (PTMs), including phosphorylation, SUMOylation, ubiquitination, acetylation, proteolytic cleavage, and palmitoylation. In the presence of the HD mutation, some PTMs are significantly altered and can result in changes in the clinical phenotype. A rate-limiting PTM is defined as one that can result in significant effects on the phenotype in animal models. For example, the prevention of proteolysis at D586 as well as constitutive phosphorylation at S13 and S16 can obviate the expression of phenotypic features of HD. The enzymes involved in these modifications such as caspase-6, the IκB kinase (IKK) complex, and still to be characterized phosphatases therefore represent promising therapeutic targets for HD. Identifying and testing specific modulators of PTMs now constitute the next big challenges in order to further validate these targets and proceed towards the goal of a mechanism-based treatment for HD.
AikenCTSteffanJSGuerreroCMKhashwjiHLukacsovichTSimmonsD, and others. 2009. Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J Biol Chem284(43):29427–36.
2.
AlbinRLYoungABPenneyJBHandelinBBalfourRAndersonKD, and others. 1990. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington’s disease. N Engl J Med322(18):1293–8.
3.
AlbrechtSBourdeauMBennettDMufsonEJBhattacharjeeMLeBlancAC. 2007. Activation of caspase-6 in aging and mild cognitive impairment. Am J Pathol170(4):1200–9.
4.
AnneSLSaudouFHumbertS. 2007. Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons. J Neurosci27(27):7318–28.
5.
ArrasateMMitraSSchweitzerESSegalMRFinkbeinerS. 2004. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature431(7010):805–10.
6.
BaquetZCGorskiJAJonesKR. 2004. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci24(17):4250–8.
7.
BerkeSJSchmiedFABruntEREllerbyLMPaulsonHL. 2004. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J Neurochem89(4):908–18.
8.
BessertDAGutridgeKLDunbarJCCarlockLR. 1995. The identification of a functional nuclear localization signal in the Huntington disease protein. Brain Res Mol Brain Res33(1):165–73.
9.
BhattacharyyaAThakurAKChellgrenVMThiagarajanGWilliamsADChellgrenBW, and others. 2006. Oligoproline effects on polyglutamine conformation and aggregation. J Mol Biol355(3):524–35.
10.
BockPEPanizziPVerhammeIM. 2007. Exosites in the substrate specificity of blood coagulation reactions. J Thromb Haemost 5 Suppl1:81–94.
11.
CavistonJPRossJLAntonySMTokitoMHolzbaurEL. 2007. Huntingtin facilitates dynein/dynactin-mediated vesicle transport. Proc Natl Acad Sci U S A104(24):10045–50.
12.
ChanHYWarrickJMAndriolaIMerryDBoniniNM. 2002. Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. Hum Mol Genet11(23):2895–904.
13.
ChenHKFernandez-FunezPAcevedoSFLamYCKaytorMDFernandezMH, and others. 2003. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell113(4):457–68.
14.
ChooYSJohnsonGVMacDonaldMDetloffPJLesortM. 2004. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet13(14):1407–20.
15.
ColinEZalaDLiotGRangoneHBorrell-PagesMLiXJ, and others. 2008. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J27(15):2124–34.
16.
Colomer GouldVFGotiDPearceDGonzalezGAGaoHBermudez de LeonM, and others. 2007. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Neurobiol Dis27(3):362–9.
17.
CrepaldiLRiccioA. 2009. Chromatin learns to behave. Epigenetics4(1):23–6.
18.
DalvaMB. 2009. Neuronal activity moves protein palmitoylation into the synapse. J Cell Biol186(1):7–9.
19.
DehayBBertolottiA. 2006. Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast. J Biol Chem281(47):35608–15.
DeyNDBombardMCRolandBPDavidsonSLuMRossignolJ, and others. 2010. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington’s disease. Behav Brain Res214(2):193–200.
22.
DiFigliaMSappEChaseKODaviesSWBatesGPVonsattelJP, and others. 1997. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science277(5334):1990–3.
23.
DixMMSimonGMCravattBF. 2008. Global mapping of the topography and magnitude of proteolytic events in apoptosis. Cell134(4):679–91.
24.
DrisdelRCManzanaEGreenWN. 2004. The role of palmitoylation in functional expression of nicotinic alpha7 receptors. J Neurosci24(46):10502–10.
25.
DuvickLABarnesJEbnerBAgrawalSAndresenMLimJ, and others. 2010. SCA1-like disease in mice expressing wild-type ataxin-1 with a serine to aspartic acid replacement at residue 776. Neuron67:929–35.
26.
EllerbyLMAndrusiakRLWellingtonCLHackamASProppSSWoodJD, and others. 1999. Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem274(13):8730–6.
27.
EmamianESKaytorMDDuvickLAZuTTouseySKZoghbiHY, and others. 2003. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron38(3):375–87.
28.
FalkJDVargiuPFoyePEUsuiHPerezJDanielsonPE, and others. 1999. Rhes: a striatal-specific Ras homolog related to Dexras1. J Neurosci Res57(6):782–8.
29.
FuMWangCReutensATWangJAngelettiRHSiconolfi-BaezL, and others. 2000. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem275(27):20853–60.
30.
FukataYFukataM. 2010. Protein palmitoylation in neuronal development and synaptic plasticity. Nat Rev Neurosci11(3):161–75.
31.
GafniJEllerbyLM. 2002. Calpain activation in Huntington’s disease. J Neurosci22(12):4842–9.
32.
GafniJHermelEYoungJEWellingtonCLHaydenMREllerbyLM. 2004. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem279(19):20211–20.
33.
GalvanVGorostizaOFBanwaitSAtaieMLogvinovaAVSitaramanS, and others. 2006. Reversal of Alzheimer’s-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci U S A103(18):7130–5.
34.
GardenGALibbyRTFuYHKinoshitaYHuangJPossinDE, and others. 2002. Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. J Neurosci22(12):4897–905.
35.
GauthierLRCharrinBCBorrell-PagesMDompierreJPRangoneHCordelieresFP, and others. 2004. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell118(1):127–38.
36.
GinesSIvanovaESeongISSauraCAMacDonaldME. 2003. Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington’s disease knock-in striatal cells. J Biol Chem278(50):50514–22.
37.
GlozakMASenguptaNZhangXSetoE. 2005. Acetylation and deacetylation of non-histone proteins. Gene363:15–23.
38.
GoldbergYPNicholsonDWRasperDMKalchmanMAKoideHBGrahamRK, and others. 1996. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet13(4):442–9.
39.
GrahamRKDengYCarrollJVaidKCowanCPouladiMA, and others. 2010. Cleavage at the 586aa caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. J Neurosci.30(45):15019–29.
40.
GrahamRKDengYSlowEJHaighBBissadaNLuG, and others. 2006a. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell125(6):1179–91.
41.
GrahamRKSlowEJDengYBissadaNLuGPearsonJ, and others. 2006b. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol Dis21(2):444–55.
42.
GrayDCMahrusSWellsJA. 2010. Activation of specific apoptotic caspases with an engineered small-molecule-activated protease. Cell142(4):637–46.
43.
GuXGreinerERMishraRKodaliROsmandAFinkbeinerS, and others. 2009. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron64(6):828–40.
44.
HaackeABroadleySABotevaRTzvetkovNHartlFUBreuerP. 2006. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3. Hum Mol Genet15(4):555–68.
45.
HaasKFBroadieK. 2008. Roles of ubiquitination at the synapse. Biochim Biophys Acta1779(8):495–506.
46.
HackamASSingarajaRWellingtonCLMetzlerMMcCutcheonKZhangT, and others. 1998. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol141(5):1097–105.
47.
HarjesPWankerEE. 2003. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci28(8):425–33.
48.
HermelEGafniJProppSSLeavittBRWellingtonCLYoungJE, and others. 2004. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington’s disease. Cell Death Differ11(4):424–38.
49.
HocklyERichonVMWoodmanBSmithDLZhouXRosaE, and others. 2003. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc Natl Acad Sci U S A100(4):2041–6.
50.
HoffnerGKahlemPDjianP. 2002. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington’s disease. J Cell Sci115(Pt 5):941–8.
51.
HuangKKangMHAskewCKangRSandersSSWanJ, and others. 2010. Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease. Neurobiol Dis40(1):207–15.
HumbertSBrysonEACordelieresFPConnorsNCDattaSRFinkbeinerS, and others. 2002. The IGF-1/Akt pathway is neuroprotective in Huntington’s disease and involves Huntingtin phosphorylation by Akt. Dev Cell2(6):831–7.
54.
JanaNRDikshitPGoswamiAKotliarovaSMurataSTanakaK, and others. 2005. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J Biol Chem280(12):11635–40.
55.
JeongHThenFMeliaTJJrMazzulliJRCuiLSavasJN, and others. 2009. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell137(1):60–72.
56.
JungJXuKLessingDBoniniNM. 2009. Preventing ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Hum Mol Genet18(24):4843–52.
57.
KalchmanMAGrahamRKXiaGKoideHBHodgsonJGGrahamKC, and others. 1996. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem271(32):19385–94.
58.
KangBSAhnJYKimMKKimHJKangLLimHC, and others. 2007. Heat shock protein 70 alters the endosome-lysosomal localization of huntingtin. Exp Mol Med39(1):38–46.
59.
KellerTHPichotaAYinZ. 2006. A practical view of ‘druggability.’Curr Opin Chem Biol10(4):357–61.
60.
KimMLeeHSLaForetGMcIntyreCMartinEJChangP, and others. 1999. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci19(3):964–73.
61.
KimYJSappECuiffoBGSobinLYoderJKegelKB, and others. 2006. Lysosomal proteases are involved in generation of N-terminal huntingtin fragments. Neurobiol Dis22(2):346–56.
62.
KobayashiYMiwaSMerryDEKumeAMeiLDoyuM, and others. 1998. Caspase-3 cleaves the expanded androgen receptor protein of spinal and bulbar muscular atrophy in a polyglutamine repeat length-dependent manner. Biochem Biophys Res Commun252(1):145–50.
63.
KruseJPGuW. 2009. Modes of p53 regulation. Cell137(4):609–22.
64.
KurokawaMKornbluthS. 2009. Caspases and kinases in a death grip. Cell138(5):838–54.
65.
LandlesCSathasivamKWeissAWoodmanBMoffittHFinkbeinerS, and others. 2010. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem285(12):8808–23.
66.
LandryYGiesJP. 2008. Drugs and their molecular targets: an updated overview. Fundam Clin Pharmacol22(1):1–18.
67.
LeavittBRvan RaamsdonkJMShehadehJFernandesHMurphyZGrahamRK, and others. 2006. Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem96(4):1121–9.
68.
LevensonJMO’RiordanKJBrownKDTrinhMAMolfeseDLSweattJD. 2004. Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem279(39):40545–59.
69.
LiMChevalier-LarsenESMerryDEDiamondMI. 2007. Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J Biol Chem282(5):3157–64.
70.
LiWSerpellLCCarterWJRubinszteinDCHuntingtonJA. 2006. Expression and characterization of full-length human huntingtin, an elongated HEAT repeat protein. J Biol Chem281(23):15916–22.
71.
LiZJoJJiaJMLoSCWhitcombDJJiaoS, and others. 2010. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. Cell141(5):859–71.
72.
LuDCRabizadehSChandraSShayyaRFEllerbyLMYeX, and others. 2000. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nat Med6(4):397–404.
73.
LunkesALindenbergKSBen-HaiemLWeberCDevysDLandwehrmeyerGB, and others. 2002. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell10(2):259–69.
74.
LuoSVacherCDaviesJERubinszteinDC. 2005. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J Cell Biol169(4):647–56.
75.
MahrusSTrinidadJCBarkanDTSaliABurlingameALWellsJA. 2008. Global sequencing of proteolytic cleavage sites in apoptosis by specific labeling of protein N termini. Cell134(5):866–76.
76.
MatsumotoMYadaMHatakeyamaSIshimotoHTanimuraTTsujiS, and others. 2004. Molecular clearance of ataxin-3 is regulated by a mammalian E4. EMBO J23(3):659–69.
77.
McGuireJRRongJLiSHLiXJ. 2006. Interaction of Huntingtin-associated protein-1 with kinesin light chain: implications in intracellular trafficking in neurons. J Biol Chem281(6):3552–9.
78.
Mende-MuellerLMToneffTHwangSRChesseletMFHookVY. 2001. Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington’s disease striatum. J Neurosci21(6):1830–7.
79.
MetzlerMGanLMazareiGGrahamRKLiuLBissadaN, and others. 2010. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J Neurosci30(43):14318–29.
80.
MetzlerMGanLWongTPLiuLHelmJGeorgiouJ, and others. 2007. NMDA receptor function and NMDA receptor-dependent phosphorylation of huntingtin is altered by the endocytic protein HIP1. J Neurosci27(9):2298–308.
81.
MillerJPHolcombJAl-RamahiIde HaroMGafniJZhangN, and others. 2010. Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington’s disease. Neuron67(2):199–212.
82.
MilnerwoodAJGladdingCMPouladiMAKaufmanAMHinesRMBoydJD, and others. 2010. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington’s disease mice. Neuron65(2):178–90.
83.
MiyashitaTOkamura-OhoYMitoYNagafuchiSYamadaM. 1997. Dentatorubral pallidoluysian atrophy (DRPLA) protein is cleaved by caspase-3 during apoptosis. J Biol Chem272(46):29238–42.
84.
MukherjeeSThomasMDadgarNLiebermanAPIniguez-LluhiJA. 2009. Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation. J Biol Chem284(32):21296–306.
85.
NikolaevAMcLaughlinTO’LearyDDTessier-LavigneM. 2009. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature457(7232):981–9.
86.
NishidaTYasudaH. 2002. PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. J Biol Chem277(44):41311–7.
87.
NoritakeJFukataYIwanagaTHosomiNTsutsumiRMatsudaN, and others. 2009. Mobile DHHC palmitoylating enzyme mediates activity-sensitive synaptic targeting of PSD-95. J Cell Biol186(1):147–60.
OkamotoSPouladiMATalantovaMYaoDXiaPEhrnhoeferDE, and others. 2009. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med15(12):1407–13.
90.
PalazzoloIBurnettBGYoungJEBrennePLLa SpadaARFischbeckKH, and others. 2007. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet16(13):1593–603.
91.
ParkKJGrossoCAAubertIKaplanDRMillerFD. 2010. p75NTR-dependent, myelin-mediated axonal degeneration regulates neural connectivity in the adult brain. Nat Neurosci13(5):559–66.
92.
PedramARazandiMSainsonRCKimJKHughesCCLevinER. 2007. A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem282(31):22278–88.
93.
PennutoMPalazzoloIPolettiA. 2009. Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. Hum Mol Genet18(R1):R40–7.
94.
PinedaJRPardoRZalaDYuHHumbertSSaudouF. 2009. Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington’s disease. Mol Brain2(1):33.
95.
PoukkaHKarvonenUJanneOAPalvimoJJ. 2000. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci U S A97(26):14145–50.
96.
PreisingerEJordanBMKazantsevAHousmanD. 1999. Evidence for a recruitment and sequestration mechanism in Huntington’s disease. Philos Trans R Soc Lond B Biol Sci354(1386):1029–34.
97.
RakhilinSDrisdelRCSagherDMcGeheeDSVallejoYGreenWN. 1999. alpha-bungarotoxin receptors contain alpha7 subunits in two different disulfide-bonded conformations. J Cell Biol146(1):203–18.
98.
RangoneHPoizatGTroncosoJRossCAMacDonaldMESaudouF, and others. 2004. The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur J Neurosci19(2):273–9.
99.
RatovitskiTGucekMJiangHChighladzeEWaldronED’AmbolaJ, and others. 2009. Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem284(16):10855–67.
100.
RatovitskiTNakamuraMD’AmbolaJChighladzeELiangYWangW, and others. 2007. N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington’s disease. Cell Cycle6(23):2970–81.
101.
RockabrandESlepkoNPantaloneANukalaVNKazantsevAMarshJL, and others. 2007. The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet16(1):61–77.
102.
RouauxCJokicNMbebiCBoutillierSLoefflerJPBoutillierAL. 2003. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J22(24):6537–49.
103.
RyuJChoSParkBCLee doH. 2010. Oxidative stress-enhanced SUMOylation and aggregation of ataxin-1: implication of JNK pathway. Biochem Biophys Res Commun393(2):280–5.
104.
SaudouFFinkbeinerSDevysDGreenbergME. 1998. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell95(1):55–66.
105.
SchillingBGafniJTorcassiCCongXRowRHLaFevre-BerntMA, and others. 2006. Huntingtin phosphorylation sites mapped by mass spectrometry: modulation of cleavage and toxicity. J Biol Chem281(33):23686–97.
106.
SchmidtkePBarrilX. 2010. Understanding and predicting druggability: a high-throughput method for detection of drug binding sites. J Med Chem53(15):5858–67.
107.
SchoenmannZAssa-KunikETiomnySMinisAHaklai-TopperLAramaE, and others. 2010. Axonal degeneration is regulated by the apoptotic machinery or a NAD+-sensitive pathway in insects and mammals. J Neurosci30(18):6375–86.
108.
SherbenouDWDrukerBJ. 2007. Applying the discovery of the Philadelphia chromosome. J Clin Invest117(8):2067–74.
109.
SlowEJGrahamRKOsmandAPDevonRSLuGDengY, and others. 2005. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A102(32):11402–7.
110.
SouthwellALKhoshnanADunnDEBuggCWLoDCPattersonPH. 2008. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci28(36):9013–20.
111.
SteffanJSAgrawalNPallosJRockabrandETrotmanLCSlepkoN, and others. 2004. SUMO modification of Huntingtin and Huntington’s disease pathology. Science304(5667):100–4.
112.
StrehlowANLiJZMyersRM. 2007. Wild-type huntingtin participates in protein trafficking between the Golgi and the extracellular space. Hum Mol Genet16(4):391–409.
113.
StrongTVTagleDAValdesJMElmerLWBoehmKSwaroopM, and others. 1993. Widespread expression of the human and rat Huntington’s disease gene in brain and nonneural tissues. Nat Genet5(3):259–65.
114.
SubramaniamSSixtKMBarrowRSnyderSH. 2009. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science324(5932):1327–30.
115.
TanJASongJChenYDurrinLK. 2010. Phosphorylation-dependent interaction of SATB1 and PIAS1 directs SUMO-regulated caspase cleavage of SATB1. Mol Cell Biol30(11):2823–36.
116.
TerashimaTKawaiHFujitaniMMaedaKYasudaH. 2002. SUMO-1 co-localized with mutant atrophin-1 with expanded polyglutamines accelerates intranuclear aggregation and cell death. Neuroreport13(17):2359–64.
117.
ThompsonLMAikenCTKaltenbachLSAgrawalNIllesKKhoshnanA, and others. 2009. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol187(7):1083–99.
118.
TrushinaEMcMurrayCT. 2007. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience145(4):1233–48.
119.
TsaiLHTakahashiTCavinessVSJrHarlowE. 1993. Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development119(4):1029–40.
120.
TsaiYCFishmanPSThakorNVOylerGA. 2003. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem278(24):22044–55.
121.
UedaHGotoJHashidaHLinXOyanagiKKawanoH, and others. 2002. Enhanced SUMOylation in polyglutamine diseases. Biochem Biophys Res Commun293(1):307–13.
122.
WalshRStoreyEStefaniDKellyLTurnbullV. 2005. The roles of proteolysis and nuclear localisation in the toxicity of the polyglutamine diseases: a review. Neurotox Res7(1–2):43–57.
123.
WangXJCaoQLiuXWangKTMiWZhangY, and others. 2010. Crystal structures of human caspase 6 reveal a new mechanism for intramolecular cleavage self-activation. EMBO Rep11:841–7.
124.
WarbySCChanEYMetzlerMGanLSingarajaRRCrockerSF, and others. 2005. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum Mol Genet14(11):1569–77.
125.
WarbySCDotyCNGrahamRKCarrollJBYangYZSingarajaRR, and others. 2008. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Hum Mol Genet17(15):2390–404.
126.
WarbySCDotyCNGrahamRKShivelyJSingarajaRRHaydenMR. 2009. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci40(2):121–7.
127.
WellingtonCLEllerbyLMHackamASMargolisRLTrifiroMASingarajaR, and others. 1998. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem273(15):9158–67.
128.
WellingtonCLHaydenMR. 2000. Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clin Genet57(1):1–10.
129.
WellingtonCLSingarajaREllerbyLSavillJRoySLeavittB, and others. 2000. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem275(26):19831–8.
130.
WilkinsonKANakamuraYHenleyJM. 2010. Targets and consequences of protein SUMOylation in neurons. Brain Res Rev64(1):195–212.
XieYHaydenMRXuBIn press. BDNF overexpression in the forebrain rescues Huntington’s disease phenotypes in YAC128 mice. J Neurosci.
133.
YanaiAHuangKKangRSingarajaRRArstikaitisPGanL, and others. 2006. Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. Nat Neurosci9(6):824–31.
134.
YangXJSetoE. 2008. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell31(4):449–61.
135.
YoungJEGouwLProppSSopherBLTaylorJLinA, and others. 2007. Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation. J Biol Chem282(41):30150–60.
136.
ZalaDColinERangoneHLiotGHumbertSSaudouF. 2008. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet17(24):3837–46.
137.
ZeronMMHanssonOChenNWellingtonCLLeavittBRBrundinP, and others. 2002. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron33(6):849–60.
138.
ZhangYLiMDrozdaMChenMRenSMejia SanchezRO, and others. 2003. Depletion of wild-type huntingtin in mouse models of neurologic diseases. J Neurochem87(1):101–6.
139.
ZuchnerTBrundinP. 2008. Mutant huntingtin can paradoxically protect neurons from death. Cell Death Differ15(3):435–42.
